These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8711090)

  • 21. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA user fees and innovation.
    Somberg J
    Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
    [No Abstract]   [Full Text] [Related]  

  • 23. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teaching the elephant to dance: privatizing the FDA review process.
    Price EC
    Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech hits regulatory doldrums.
    Lawrence S
    Nat Biotechnol; 2005 Jun; 23(6):644. PubMed ID: 15940226
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA begins product approval initiative.
    Lewis C
    FDA Consum; 2003; 37(3):10-1. PubMed ID: 12793386
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA looks at full approval for d4T. Food and Drug Administration.
    Posit Aware; 1996; 7(1):7. PubMed ID: 11363131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
    Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
    Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
    Alper K; Schwartz KA; Kolts RL; Khan A
    Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drug approvals for 2002.
    Frantz S; Smith A
    Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
    [No Abstract]   [Full Text] [Related]  

  • 33. Perspectives. Approval process a moving target in FDA reform hearings.
    Rhein R
    Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA notifications. FDA: tentative approval of generic nevirapine.
    AIDS Alert; 2008 Jul; 23(7):80-1. PubMed ID: 18693339
    [No Abstract]   [Full Text] [Related]  

  • 35. The numbers game.
    Nat Rev Drug Discov; 2002 Dec; 1(12):929. PubMed ID: 12474850
    [No Abstract]   [Full Text] [Related]  

  • 36. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA publishes analysis of the pipeline problem.
    Frantz S
    Nat Rev Drug Discov; 2004 May; 3(5):379. PubMed ID: 15152628
    [No Abstract]   [Full Text] [Related]  

  • 38. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA issues regulations on accelerated drug-approval process.
    Clin Pharm; 1993 Apr; 12(4):253-4. PubMed ID: 8458175
    [No Abstract]   [Full Text] [Related]  

  • 40. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.